Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faster-acting Insulin Aspart Postprandial Glucose Metabolism in T1D
NCT02568280Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2015
- Primary completion
- Apr 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin aspart in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Mean change in plasma glucose concentration. Started Oct 2015; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02568280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02568280.